The conversation about Wegovy Medicare coverage has shifted dramatically in the past two years. What was once a flat “no” for all Medicare beneficiaries is now a qualified “yes” for patients who meet specific cardiovascular disease criteria. This guide explains exactly what Medicare Part D pays for in 2026, who qualifies, how the $2,000 out-of-pocket cap interacts with Wegovy, and what to do if your plan denies your prior authorization.
How Medicare Part D Traditionally Treated Weight-Loss Drugs
Medicare Part D — the prescription drug benefit added to Medicare in 2003 — excluded several drug categories from required coverage. Among them were “drugs used for weight loss.” This was a statutory decision made by Congress, not a clinical judgment by Medicare. For 20 years, it meant that Wegovy, Saxenda, Qsymia, and phentermine were uniformly uncovered by Medicare, regardless of patient need.
The Centers for Medicare and Medicaid Services has consistently interpreted this exclusion strictly. Only when a medication earns a non-weight-loss FDA indication does the exclusion no longer apply. This technical point became the key to Wegovy’s path into Medicare coverage.
The 2024 Cardiovascular Indication Change
In March 2024, the FDA approved Wegovy for reducing cardiovascular death, heart attack, and stroke risk in adults with established cardiovascular disease and obesity or overweight. This approval was based on results from the SELECT trial, a major outcomes study showing Wegovy reduced major adverse cardiovascular events by 20 percent in the trial population. You can read the full results in the New England Journal of Medicine publication of SELECT.
Following the FDA approval, CMS issued guidance stating that Wegovy prescribed for cardiovascular risk reduction could be covered by Part D plans because the use was no longer classified as purely weight loss. Individual Part D plans began adding Wegovy to their formularies under this new indication starting in mid-2024.
Who Qualifies for Medicare Wegovy Coverage
To qualify under Medicare, a patient must meet all of these criteria: enrollment in a Medicare Part D plan or Medicare Advantage plan with prescription drug coverage, established cardiovascular disease (documented prior MI, stroke, symptomatic peripheral artery disease, or coronary artery disease), and either obesity (BMI 30+) or overweight (BMI 27-29.9).
The cardiovascular disease documentation is the crucial part. Patients with only hypertension, dyslipidemia, or diabetes — but no history of a major cardiovascular event or established CAD — do not qualify under the current indication. Your prescribing clinician must be willing to document the qualifying diagnosis in your medical record and on the prior authorization form.
How Prior Authorization Works
Prior authorization is required for Wegovy Medicare prescriptions in virtually all Part D plans. The process starts when your prescriber submits the PA form through the plan’s electronic portal or fax. Required documentation typically includes the ICD-10 code for your cardiovascular diagnosis, BMI calculation, and a clinical statement connecting Wegovy to cardiovascular risk reduction rather than weight loss alone.
Plans must decide on a standard PA within 72 hours and an expedited PA within 24 hours per CMS regulations. If approved, the plan will specify any quantity limits and refill rules. If denied, you receive a written explanation and information about how to appeal.
The 2026 $2,000 Out-of-Pocket Cap
One of the most significant changes for Medicare beneficiaries on Wegovy is the $2,000 annual out-of-pocket cap on Part D prescriptions. This cap, which took full effect in 2025 and applies in 2026, means no beneficiary can pay more than $2,000 in out-of-pocket prescription costs in a calendar year for covered medications.
For a Wegovy patient who qualifies under Medicare, this cap is transformative. Before 2025, beneficiaries could face thousands of dollars in coverage-gap (donut hole) costs for specialty drugs. Now, once you hit $2,000 for the year, Medicare covers the rest. Additionally, the Medicare Prescription Payment Plan lets you spread your out-of-pocket costs evenly across the year rather than paying large amounts upfront.
Medicare Advantage vs Standalone Part D
Medicare Advantage (Part C) plans and standalone Medicare Part D plans both cover prescription drugs under the Part D framework. Each plan sets its own formulary within CMS rules. In 2026, most Medicare Advantage plans include Wegovy on formulary for patients meeting the cardiovascular indication, though the copay tier varies.
During Medicare Open Enrollment (October 15 to December 7), you can compare plans using the Medicare.gov plan finder tool. Enter “Wegovy” in the medication list to see which plans cover it, the copay or coinsurance tier, and any restrictions like quantity limits. Related: full Medicare Wegovy coverage breakdown.
What to Do If Denied
Medicare has a clearly defined appeals process with five levels. Level one is a redetermination by the Part D plan itself, which must be requested within 60 days of the denial. Level two is reconsideration by an independent review entity. Higher levels include an Administrative Law Judge hearing, the Medicare Appeals Council, and federal court review.
Most appeals succeed at level one or two with additional clinical documentation. Work with your prescriber to gather the strongest evidence of your cardiovascular disease — hospital discharge summaries, cardiologist consultation notes, imaging reports, and stress test results. A clear, well-supported appeal has a substantially higher success rate than a bare-bones resubmission.
Frequently Asked Questions
Does every Medicare Part D plan cover Wegovy?
No. Plans have discretion in formulary design. Most major national Part D plans added Wegovy to their formularies in 2024-2025, but specific coverage and tier placement vary. Check your plan’s formulary or Medicare.gov plan finder during open enrollment.
Can I get Wegovy covered by Medicare if I only want weight loss?
Not under the current statutory exclusion. Medicare covers Wegovy only for the cardiovascular risk reduction indication, which requires documented cardiovascular disease. Weight loss alone remains excluded from Part D coverage.
How much does Wegovy cost under Medicare in 2026?
Out-of-pocket costs are capped at $2,000 per year for all covered Part D prescriptions combined. Monthly copays vary by plan — typically $50 to $200 per month until you hit the cap. The Medicare Prescription Payment Plan can spread these costs evenly across the year.
What if my Medicare plan denies my Wegovy prior authorization?
Request a written denial and review the reason. Work with your prescriber to strengthen the clinical documentation and file a redetermination request within 60 days. Appeals often succeed at the first or second level with additional evidence of cardiovascular disease.
Does Original Medicare (without Part D) cover Wegovy?
No. Original Medicare Parts A and B do not include outpatient prescription drug coverage. To have any possibility of Wegovy coverage, you need Part D or a Medicare Advantage plan with drug coverage. See what insurance covers Wegovy for weight loss.
Your Next Step With Wegovy and Medicare
Check your current Part D or Medicare Advantage plan’s formulary for Wegovy, either through your plan’s member portal or Medicare.gov. If you have cardiovascular disease history and a BMI of 27 or higher, discuss eligibility with your prescribing clinician and request they submit a prior authorization with full documentation.
The healthcare policy pillar and our Wegovy insurance coverage guide cover broader context on public and private insurance rules. Medicare’s treatment of Wegovy is evolving — staying current with your plan’s specific rules is essential to actually accessing coverage.